Skip to main content
. 2020 Jul 17;25:100459. doi: 10.1016/j.eclinm.2020.100459

Fig. 1.

Fig 1

Kaplan-Meier survival curve for tocilizumab (blue line) and control (violet line) group. Analysis run using Group (tocilizumab vs controls) as factor; death as event and time to death/discharge as time variable. Multivariate Hazard Ratio (H.R. for death: 0.057; 95% C.I = 0.017- 0.187, p < 0.001) is adjusted for baseline characteristics.